Laurus Labs Limited — Capital/Financing Update 2023

Jul 12, 2023

==> picture [452 x 75] intentionally omitted <==

July 12, 2023

ToThe Corporate Relations DepartmentBSE LimitedPhiroz Jeejeebhoy Towers, 25thFloor,Dalal StreetMumbai – 400001Code: 540222	ToThe Listing DepartmentNational Stock Exchange of India Limited,Exchange Plaza,Bandra Kurla Complex, Bandra (East)Mumbai – 400 051Code: LAURUSLABS

Sub: Update on Investment in M/s. Immunoadoptive Cell Therapy Private Limited

Ref: Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 dated May 31, 2023

Dear Sirs,

This has reference to our disclosure dated May 31, 2023 regarding the signing of definitive agreements to acquire additional stake of 7.24% (on fully diluted basis) in Immunoadoptive Cell Therapy Private Limited (lmmunoACT), an advanced cell and gene therapy company for a cash consideration of Rs. 80 Crores.

In this regard, we wish to update that the Company has paid the subscription amount of Rs. 48.01 Crores (Rupees Forty Eight Crores and One Lakhs only) as “Tranche 1 Subscription Amount”.

This is for your information and record.

Yours faithfully,

For Laurus Labs Limited

Digitally signed by VENKATESWAR VENKATESWAR REDDY REDDY GOGIREDDY GOGIREDDY Date: 2023.07.12 18:15:01 +05'30' G. Venkateswar Reddy Company Secretary

==> picture [452 x 43] intentionally omitted <==